Changes in neurocognitive assessment scores after initiating dolutegravir- versus elvitegravir-based antiretroviral therapy

References

• Calcagno, A., Di Perri, G., & Bonora, S. (2017). Treating HIV infection in the central nervous system. Drugs, 77(2), 145–157. https://doi.org/https://doi.org/10.1007/s40265-016-0678-9
   PubMed Web of Science ®Google Scholar
• Calcagno, A., Simiele, M., Motta, I., Mornese Pinna, S., Bertucci, R., D’Avolio, A., Di Perri, G., & Bonora, S. (2016). Elvitegravir/cobicistat/tenofovir/emtricitabine penetration in the cerebrospinal fluid of three HIV-positive patients. AIDS Research and Human Retroviruses, 32(5), 409–411. https://doi.org/https://doi.org/10.1089/aid.2015.0337
   PubMed Web of Science ®Google Scholar
• Carvalhal, A., Gill, M. J., Letendre, S. L., Rachlis, A., Bekele, T., Raboud, J., Burchell, A., & Rourke, S. B. (2016). Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV treatment network cohort study. Journal of Neurovirology, 22(3), 349–357. https://doi.org/https://doi.org/10.1007/s13365-015-0404-5
   PubMed Web of Science ®Google Scholar
• Chan, P., & Brew, B. J. (2014). HIV associated neurocognitive disorders in the modern antiviral treatment era: Prevalence, characteristics, biomarkers, and effects of treatment. Current HIV/AIDS Reports, 11(3), 317–324. https://doi.org/https://doi.org/10.1007/s11904-014-0221-0
   PubMed Web of Science ®Google Scholar
• Chan, L. G., Kandiah, N., & Chua, A. (2012). HIV-associated neurocognitive disorders (HAND) in a South Asian population – contextual application of the 2007 criteria. BMJ Open, 2, e000662. https://doi.org/10.1136/bmjopen-2011-000662
   PubMed Web of Science ®Google Scholar
• Chertkow, H., Nasreddine, Z., Johns, E., Phillips, N., & McHenry, C. (2011). The Montreal cognitive assessment (MOCA): Validation of alternate forms and new recommendations for education corrections. Alzheimer’s & Dementia, 7(Suppl. 1), S157. https://doi.org/10.1016/j.jalz.2011.05.423
   Google Scholar
• Clifford, K. M., Samboju, V., Cobigo, Y., Milanini, B., Marx, G. A., Hellmuth, J. M., Rosen, H. J., Kramer, J. H., Allen, I. E., & Valcour, V. G. (2017). Progressive brain atrophy despite persistent viral suppression in HIV patients older than 60 years. JAIDS Journal of Acquired Immune Deficiency Syndromes, 76(3), 289–297. https://doi.org/https://doi.org/10.1097/QAI.0000000000001489
   PubMed Web of Science ®Google Scholar
• Guaraldi, G., Orlando, G., Zona, S., Menozzi, M., Carli, F., Garlassi, E., Berti, A., Rossi, E., Roverato, A., & Palella, F. (2011). Premature age-related comorbidities among HIV-infected persons compared with the general population. Clinical Infectious Diseases, 53(11), 1120–1126. https://doi.org/https://doi.org/10.1093/cid/cir627
   PubMed Web of Science ®Google Scholar
• Guerveno, C., Raymond, S., Metsu, D., Gandia, P., Izopet, J., Martin-Blondel, G., & Delobel, P. (2019). HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy. AIDS, 33(3), 593–559. https://doi.org/https://doi.org/10.1097/QAD.0000000000002089
   PubMed Web of Science ®Google Scholar
• Hasbun, R., Eraso, J., Ramireddy, S., Wainwright, D., Salazar, L., Grimes, R., York, M., & Strutt, A. (2012). Screening for neurocognitive impairment in HIV individuals: The utility of the Montreal cognitive assessment test. Journal of AIDS & Clinical Research, 3(10), 186. https://doi.org/https://doi.org/10.4172/2155-6113.1000186
   PubMedGoogle Scholar
• Hasse, B., Ledergerber, B., Furrer, H., Battegay, M., Hirschel, B., Cavassini, M., Bertisch, B., Bernasconi, E., & Weber, R. (2011). Morbidity and aging in HIV-infected persons: The Swiss HIV cohort study. Clinical Infectious Diseases, 53(11), 1130–1139. https://doi.org/https://doi.org/10.1093/cid/cir626
   PubMed Web of Science ®Google Scholar
• Heaton, R. K., Franklin, D. R., Ellis, R. J., McCutchan, J. A., Letendre, S. L., Leblanc, S., Corkran, S. H., Duarte, N. A., Clifford, D. B., Woods, S. P., Collier, A. C., Marra, C. M., Morgello, S., Mindt, M. R., Taylor, M. J., Marcotte, T. D., Atkinson, J. H., Wolfson, T., Gelman, B. B., … Grant, I. (2011). HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. Journal of Neurovirology, 17(1), 3–16. https://doi.org/https://doi.org/10.1007/s13365-010-0006-1
   PubMed Web of Science ®Google Scholar
• Letendre, S. L. (2011). Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Topics in Antiviral Medicine, 19(4), 137–142.
   PubMedGoogle Scholar
• Letendre, S. L., Ellis, R. J., Ances, B. M., & McCutchan, J. A. (2010). Neurologic complications of HIV disease and their treatment. Topics in HIV Medicine, 18(2), 45–55.
   PubMedGoogle Scholar
• Letendre, S., Marquie-Beck, J., Capparelli, E., Best, B., Clifford, D., Collier, A. C., Gelman, B. B., McArthur, J. C., McCutchan, J. A., Morgello, S., Simpson, D., Grant, I., … Ellis, R. J. (2008). Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Archives of Neurology, 65(1), 65–70. https://doi.org/https://doi.org/10.1001/archneurol.2007.31
   PubMed Web of Science ®Google Scholar
• Letendre, S. L., Mills, A. M., Tashima, K. T., Thomas, D. A., Min, S. S., Chen, S., Song, I. H., & Piscitelli, S. C. (2014). ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clinical Infectious Diseases, 59(7), 1032–1037. https://doi.org/https://doi.org/10.1093/cid/ciu477
   PubMed Web of Science ®Google Scholar
• Ma, Q., Ocque, A. J., Morse, G. D., Sanders, C., Burgi, A., Little, S. J., & Letendre, S. L. (2018, March). Switching to TAF in EVG-based Regimens: CSF Pharmacokinetics and Antiviral Activity. Poster presented at the Conference on Retroviruses and Opportunistic Infections, Boston, MA. Poster 473.
   Google Scholar
• Mind Exchange Working Group. (2013). Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: A consensus report of the mind exchange program. Clinical Infectious Diseases, 56(7), 1004–1017. https://doi.org/https://doi.org/10.1093/cid/cis975
   PubMed Web of Science ®Google Scholar
• Morgan, E. E., Woods, S. P., Scott, J. C., Childers, M., Beck, J. M., Ellis, R. J., Grant, I., & Heaton, R. K. (2008). Predictive validity of demographically adjusted normative standards for the HIV dementia scale. Journal of Clinical and Experimental Neuropsychology, 30(1), 83–90. https://doi.org/https://doi.org/10.1080/13803390701233865
   PubMed Web of Science ®Google Scholar
• Mukerji, S. S. (2017, Oct). HIV in the Brain. Managing Comorbidities in Patients with HIV. Symposium at IDWeek 2017, San Diego, CA.
   Google Scholar
• Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005). The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695–699. https://doi.org/https://doi.org/10.1111/j.1532-5415.2005.53221.x
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. (2019, December 18). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
   Google Scholar
• Sacktor, N., Skolasky, R. L., Seaberg, E., Munro, C., Becker, J. T., Martin, E., Ragin, A., Levine, A., & Miller, E. (2016). Prevalence of HIV-associated neurocognitive disorders in the multicenter AIDS cohort study. Neurology, 86(4), 334–340. https://doi.org/https://doi.org/10.1212/WNL.0000000000002277
   PubMed Web of Science ®Google Scholar
• Skinner, S., Adewale, A. J., DeBlock, L., Gill, M. J., & Power, C. (2009). Neurocognitive screening tools in HIV/AIDS: Comparative performance among patients exposed to antiretroviral therapy. HIV Medicine, 10(4), 246–252. https://doi.org/https://doi.org/10.1111/j.1468-1293.2008.00679.x
   PubMed Web of Science ®Google Scholar
• Tiraboschi, J., Imaz, A., Khoo, S., Niubo, J., Prieto, P., Saumoy, M., Penchala, S. D., Garcia, B., Padilla, C., Videla, S., … Podzamczer, D. (2019). Total and unbound bictegravir concentrations and viral suppression in CSF of HIV-infected patients (Spanish HIV/AIDS research network, PreEC/RIS 56). Journal of Infectious Diseases, Advance online publication. https://doi.org/https://doi.org/10.1093/infdis/jiz624
   Google Scholar